Pharmafile Logo
Pharmafocus logo
Advanced Search

Cancer

Showing 15 posts of 1067 posts found.

Puma Biotech’s breast cancer drug authorised by European Commission, despite prior concerns

September 5, 2018
Research and Development Cancer, EU, breast cancer, ec approval, puma biotechnology

Puma Biotechnology have received European Commission marketing authorisation for Nerlynx (neratinib) despite prior concerns as to the safety and efficacy …

News
shutterstock_192094955_web

Widening the focus on innovations in cancer treatment

September 3, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 23andME, CRUK, Cancer, GSK, diagnosis, genetics, oncology, pharma

Cancer treatment is making leaps and bounds, but public focus tends to gravitate towards the therapies themselves. Matt Fellows explores …

Feature
pharmafocus_oct_2018

The September 2018 issue of Pharmafocus is available to read online now!

September 3, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, AstraZeneca, Cancer, Iraw, J&J, JJ, Pfizer, Roche, UK, brexit, drug safety, pharma, pharmacovigilance

The new September edition of Pharmafocus is now live and available to read online. We’re entering the final stretch as …

News

AI used to forecast cancer progression

September 3, 2018
Sales and Marketing AI, Cancer, ICR, London, ai drug research and development, university of edinburgh

A team of scientists at the Institute of Cancer Research (ICR) in London and the University of Edinburgh have developed …

News
shire_image

Shire hands over its oncology franchise to Servier for $2.4bn

August 31, 2018
Medical Communications, Sales and Marketing Cancer, Servier, Shire, oncology, pharma, sale

Shire has completed the sale of its oncology franchise to French firm Servier for $2.4 billion, handing over the global …

News
european_commission_web

Novartis’ Kymriah & Gilead’s Yescarta become first EU-approved CAR T therapies

August 28, 2018
Manufacturing and Production, Sales and Marketing CAR T, CAR-T, Cancer, EU, Gilead, Kymriah, Novartis, UK, Yescarta, blood cancer, pharma

Almost one full year since the treatment was given a “historic” approval in the US, Novartis’ CAR T therapy Kymriah …

News
novartis_window

Novartis’ investigational combo impresses in breast cancer sub-group

August 23, 2018
Research and Development Cancer, Novartis, breast cancer, fulvestrant, pharma

Novartis has revealed positive new data for its investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) combined with fulvestrant in the treatment …

News
astrazeneca_sign_sky

Japan approves AstraZeneca’s Tagrisso in EGFRm non-small cell lung cancer

August 21, 2018
Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, Japan, Tagrisso, lung cancer, pharma

AstraZeneca has revealed that its EGFR tyrosine kinase inhibitor Tagrisso (osimertinib) has been approved in Japan by the nation’s Ministry …

News

Chinese regulators approve Roche’s Alecensa in regulatory shift

August 20, 2018
Sales and Marketing Cancer, China, Roche, approval, lung cancer

China’s National Drug Administration has granted rapid approval for Roche’s lung cancer treatment Alecensa (alectinib). Chinese regulators have in the …

News
cancer-vs-alzheimer-1080x810

“Radical radiotherapy” cuts required treatments from 37 to 5

August 14, 2018
Manufacturing and Production Cancer, oncology, pharma, radiotherapy

Researchers at Queen’s University Belfast have been trialling a new form of “radical radiotherapy” which can be delivered in just …

News
3922609891_dced293244_z

Rare lung cancer drug approved in Scotland

August 14, 2018
Manufacturing and Production Cancer, SMC, Scotland, Scottish Medicines Consortium, approval, lung cancer

The Scottish Medicines Consortium has approved Roche’s cancer drug alectinib for the treatment of patients with untreated advanced non-small-cell lung …

News
nhs_sign

NHS scraps restriction on availability of J&J’s Imbruvica in leukaemia patients

August 10, 2018
Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, NHS, NICE, UK, imbruvica, leukaemia, pharma

The NHS has dropped a controversial restriction preventing leukaemia patients from accessing Johnson & Johnson’s tyrosine kinase inhibitor Imbruvica (ibrutinib), …

News
800px-t_lymphocyte_16760076824

Regeneron Pharma and Bluebird bio announce immune cell collaboration

August 6, 2018
Sales and Marketing Cancer, Regeneron, Shares, bluebird, collaboration, t cells, t-cells

Regeneron Pharmaceuticals have announced that they will collaborate with the Massachusetts-based gene therapy specialist Bluebird bio in an effort to …

News

Novartis hands over global rights for two oncology drugs to Shanghai’s Laekna

August 2, 2018
Sales and Marketing Cancer, Laekna, Novartis, oncology, pharma

Novartis has revealed that it has jettisoned two of its clinical stage oncology products along with exclusive global development and …

News
rowa_vmax

Biosimilars and generics saved NHS £324m last year

August 2, 2018
Medical Communications, Sales and Marketing Cancer, NHS, biosimilars, funding, generics

The NHS watchdog, NHS Improvement, has revealed that the British National Health Service saved £324 million last financial year by …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026